The 20-year study showed the test provided an accurate assessment of the risk of long-term metastases and mortality for patients with localized prostate cancer.
The company is getting ready to offer cancer patients every type of molecular cancer diagnostics, including testing for minimal residual disease.
The study, which showed that the disease may not only result from tobacco exposure as previously thought, could lay the groundwork for targeted therapies.
NCI researchers performed a multi-platform study to elucidate the factors that can contribute to a patient's better-than-expected response to a drug.
The research showed that atezolizumab plus nab-paclitaxel provided survival benefits, as did an antibody-drug conjugate that was recently approved by the FDA.
Two new studies show that patients with advanced HR-positive, HER2-negative breast cancer had higher survival when they received combination therapies.
The company's approach combines whole-genome sequencing, CRISPR, liquid biopsy, and gene therapy to target cancer cells with gene fusions.
The biopharma company is evaluating its experimental immunotherapy against HPV-positive cancers alone and in combination with a bifunctional fusion protein.
In a separate study, researchers studying the use of Oncotype DX in African-American men found it to be predictive of disease outcomes regardless of race.
Nationwide Children's Reports High Diagnostic Yield of Combined DNA, RNA Analysis in Pediatric Cancers
Comprehensive analysis by a team led by Elaine Mardis has given 93 percent of around 150 pediatric cancer patients at least one medically actionable finding.